These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30380731)

  • 1. mRNA-Expression of
    Eckstein M; Wirtz RM; Gross-Weege M; Breyer J; Otto W; Stoehr R; Sikic D; Keck B; Eidt S; Burger M; Bolenz C; Nitschke K; Porubsky S; Hartmann A; Erben P
    Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30380731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment.
    Ecke TH; Voß PC; Schlomm T; Rabien A; Friedersdorff F; Barski D; Otto T; Waldner M; Veltrup E; Linden F; Hake R; Eidt S; Roggisch J; Heidenreich A; Rieger C; Kastner L; Hallmann S; Koch S; Wirtz RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
    Jütte H; Reike M; Wirtz RM; Kriegmair M; Erben P; Tully K; Weyerer V; Eckstein M; Hartmann A; Eidt S; Wezel F; Bolenz C; Tannapfel A; Noldus J; Roghmann F
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34073233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
    Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
    BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
    Sikic D; Taubert H; Wirtz RM; Breyer J; Eckstein M; Weyerer V; Kubon J; Erben P; Bolenz C; Burger M; Hartmann A; Wullich B; Wach S; Keck B
    Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34209360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer.
    Razzaghdoust A; Ghajari M; Basiri A; Torbati PM; Jafari A; Fattahi MR; Salahi M; Mofid B
    Investig Clin Urol; 2021 May; 62(3):274-281. PubMed ID: 33943049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer.
    Uysal D; Kowalewski KF; Kriegmair MC; Wirtz R; Popovic ZV; Erben P
    PLoS One; 2021; 16(3):e0248342. PubMed ID: 33711044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes.
    Ramírez-Backhaus M; Fernández-Serra A; Rubio-Briones J; Cruz Garcia P; Calatrava A; Garcia Casado Z; Casanova Salas I; Rubio L; Solsona E; López-Guerrero JA
    Actas Urol Esp; 2015 Oct; 39(8):473-81. PubMed ID: 25920992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy.
    Sikic D; Eckstein M; Wirtz RM; Jarczyk J; Worst TS; Porubsky S; Keck B; Kunath F; Weyerer V; Breyer J; Otto W; Rinaldetti S; Bolenz C; Hartmann A; Wullich B; Erben P
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort.
    Weyerer V; Stoehr R; Bertz S; Lange F; Geppert CI; Wach S; Taubert H; Sikic D; Wullich B; Hartmann A; Eckstein M
    World J Urol; 2021 Nov; 39(11):4011-4019. PubMed ID: 34259899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trp53 Mutation in Keratin 5 (Krt5)-Expressing Basal Cells Facilitates the Development of Basal Squamous-Like Invasive Bladder Cancer in the Chemical Carcinogenesis of Mouse Bladder.
    Masuda N; Murakami K; Kita Y; Hamada A; Kamada M; Teramoto Y; Sakatani T; Matsumoto K; Sano T; Saito R; Okuno Y; Ogawa O; Kobayashi T
    Am J Pathol; 2020 Aug; 190(8):1752-1762. PubMed ID: 32339497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers vs conventional histological analysis to detect lymph node micrometastases in bladder cancer: a real improvement?
    Gazquez C; Ribal MJ; Marín-Aguilera M; Kayed H; Fernández PL; Mengual L; Alcaraz A
    BJU Int; 2012 Nov; 110(9):1310-6. PubMed ID: 22416928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.
    Hoffman-Censits JH; Lombardo KA; Parimi V; Kamanda S; Choi W; Hahn NM; McConkey DJ; McGuire BM; Bivalacqua TJ; Kates M; Matoso A
    Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):619-625. PubMed ID: 33901032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Cell-Associated Protein Expression Helps to Predict Survival in Muscle-Invasive Urothelial Bladder Cancer Patients after Radical Cystectomy and Optional Adjuvant Chemotherapy.
    Taubert H; Eckstein M; Epple E; Jung R; Weigelt K; Lieb V; Sikic D; Stöhr R; Geppert C; Weyerer V; Bertz S; Kehlen A; Hartmann A; Wullich B; Wach S
    Cells; 2021 Jan; 10(1):. PubMed ID: 33467469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of genes correlated with early-stage bladder cancer progression.
    Stone R; Sabichi AL; Gill J; Lee IL; Adegboyega P; Dai MS; Loganantharaj R; Trutschl M; Cvek U; Clifford JL
    Cancer Prev Res (Phila); 2010 Jun; 3(6):776-86. PubMed ID: 20501863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
    Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
    Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.